Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers:: a case-control study

被引:73
|
作者
Narod, Steven A.
Lubinski, Jan
Ghadirian, Parviz
T Lynch, Henry
Moller, Pal
Foulkes, William D.
Rosen, Barry
Kim-Sing, Charmaine
Isaacs, Claudine
Domcheck, Susan
Sun, Ping
机构
[1] Univ Toronto, Ctr Res Womens Hlth, Toronto, ON M5G 1N8, Canada
[2] Pomeranian Med Univ, Szczecin, Poland
[3] Univ Montreal, Cent Hosp Univ Montreal Hotel Dieu, Epidemiol Res Unit, Montreal, PQ, Canada
[4] Creighton Univ, Sch Med, Dept Prevent Med & Publ Hlth, Omaha, NE USA
[5] Norwegian Radium Hosp, Dept Canc Genet, Oslo, Norway
[6] McGill Univ, Dept Oncol & Human Genet, Program Canc Genet, Montreal, PQ, Canada
[7] Univ Hlth Network, Dept Gynecol, Toronto, ON, Canada
[8] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[9] Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA
[10] Univ Penn, Dept Med, Philadelphia, PA 19104 USA
[11] Univ Penn, Dept Genet, Philadelphia, PA 19104 USA
来源
LANCET ONCOLOGY | 2006年 / 7卷 / 05期
关键词
D O I
10.1016/S1470-2045(06)70624-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Screening mammography is associated with a small dose of radiation to the breast, and women with increased genetic risk might be particularly sensitive to the DNA-damaging effects of ionising radiation. We aimed to assess whether exposure to ionising radiation through mammography screening was associated with risk of breast cancer in BRCA1 or BRCA2 mutation carriers. Methods We identified 1600 cases of breast cancer and 1600 controls without breast cancer who were matched for BRCA mutation, date of birth (within 1 year), and country of residence from an international registry of BRCA1 and BRCA2 mutation carriers. We used a questionnaire to inquire about whether participants had ever had screening mammography, and, if so, the age at which they first had the procedure. Results We found no association between ever having screening mammography and risk of breast cancer (odds ratio [OR] 1.03 [95% CI 0.85-1.25], adjusted for parity, oral-contraceptive use, ethnic origin, and bilateral oophorectomy). The association was much the same for BRCA1 mutation carriers and BRCA2 mutation carriers (1.04 [0.84-1.29] vs 1.06 [0.67-1.66], respectively, adjusted for parity, oral-contraceptive use, ethnic origin, and bilateral oophorectomy). Interpretation These findings do not lend support to the idea that exposure to ionising radiation through routine screening mammography contributes substantially to the burden of breast cancer in BRCA1 and BRCA2 mutation carriers. Prospective studies are needed to confirm the results of this initial report, and, where possible, these studies should assess a more appropriate endpoint of total exposure.
引用
收藏
页码:402 / 406
页数:5
相关论文
共 50 条
  • [31] Oral Contraceptives and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
    Figueiredo, Jane C.
    Haile, Robert W.
    Bernstein, Jonine L.
    [J]. CURRENT BREAST CANCER REPORTS, 2009, 1 (03) : 139 - 147
  • [32] Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers
    Mitchell, G
    Antoniou, AC
    Warren, R
    Peock, S
    Brown, J
    Davies, R
    Mattison, J
    Cook, M
    Warsi, I
    Evans, DG
    Eccles, D
    Douglas, F
    Paterson, J
    Hodgson, S
    Izatt, L
    Cole, T
    Burgess, L
    Eeles, R
    Easton, DF
    [J]. CANCER RESEARCH, 2006, 66 (03) : 1866 - 1872
  • [33] Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    Joanne Kotsopoulos
    Jan Lubinski
    Henry T. Lynch
    Susan L. Neuhausen
    Parviz Ghadirian
    Claudine Isaacs
    Barbara Weber
    Charmaine Kim-Sing
    William D. Foulkes
    Ruth Gershoni-Baruch
    Peter Ainsworth
    Eitan Friedman
    Mary Daly
    Judy E. Garber
    Beth Karlan
    Olufunmilayo I. Olopade
    Nadine Tung
    Howard M. Saal
    Andrea Eisen
    Michael Osborne
    Hakan Olsson
    Dawna Gilchrist
    Ping Sun
    Steven A. Narod
    [J]. Cancer Causes & Control, 2005, 16 : 667 - 674
  • [34] Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
    Phillips, Kelly-Anne
    Milne, Roger L.
    Rookus, Matti A.
    Daly, Mary B.
    Antoniou, Antonis C.
    Peock, Susan
    Frost, Debra
    Easton, Douglas F.
    Ellis, Steve
    Friedlander, Michael L.
    Buys, Saundra S.
    Andrieu, Nadine
    Nogues, Catherine
    Stoppa-Lyonnet, Dominique
    Bonadona, Valerie
    Pujol, Pascal
    McLachlan, Sue Anne
    John, Esther M.
    Hooning, Maartje J.
    Seynaeve, Caroline
    Tollenaar, Rob A. E. M.
    Goldgar, David E.
    Terry, Mary Beth
    Caldes, Trinidad
    Weideman, Prue C.
    Andrulis, Irene L.
    Singer, Christian F.
    Birch, Kate
    Simard, Jacques
    Southey, Melissa C.
    Olsson, Hakan L.
    Jakubowska, Anna
    Olah, Edith
    Gerdes, Anne-Marie
    Foretova, Lenka
    Hopper, John L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (25) : 3091 - 3099
  • [35] Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers
    Oden, Lovisa
    Akbari, Mohammad
    Zaman, Tasnim
    Singer, Christian F.
    Sun, Ping
    Narod, Steven A.
    Salmena, Leonardo
    Kotsopoulos, Joanne
    [J]. ONCOTARGET, 2016, 7 (52) : 86687 - 86694
  • [36] Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers
    Antoniou, Antonis C.
    Shenton, Andrew
    Maher, Eamonn R.
    Watson, Emma
    Woodward, Emma
    Lalloo, Fiona
    Easton, Douglas F.
    Evans, D. Gareth
    [J]. BREAST CANCER RESEARCH, 2006, 8 (06)
  • [37] Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers
    Roger L. Milne
    Ana Osorio
    Teresa Ramón y Cajal
    Montserrat Baiget
    Adriana Lasa
    Eduardo Diaz-Rubio
    Miguel de la Hoya
    Trinidad Caldés
    Alex Teulé
    Conxi Lázaro
    Ignacio Blanco
    Judith Balmaña
    Gessamí Sánchez-Ollé
    Ana Vega
    Ana Blanco
    Isabel Chirivella
    Eva Esteban Cardeñosa
    Mercedes Durán
    Eladio Velasco
    Eduardo Martínez de Dueñas
    María-Isabel Tejada
    María-Dolores Miramar
    María-Teresa Calvo
    Carmen Guillén-Ponce
    Raquel Salazar
    Carlos San Román
    Miguel Urioste
    Javier Benítez
    [J]. Breast Cancer Research and Treatment, 2010, 119 : 221 - 232
  • [38] Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    Kotsopoulos, J
    Lubinski, J
    Lynch, HT
    Neuhausen, SL
    Ghadirian, P
    Isaacs, C
    Weber, B
    Kim-Sing, C
    Foulkes, WD
    Gershoni-Baruch, R
    Ainsworth, P
    Friedman, E
    Daly, M
    Garber, JE
    Karlan, B
    Olopade, OI
    Tung, N
    Saal, HM
    Eisen, A
    Osborne, M
    Olsson, H
    Gilchrist, D
    Sun, P
    Narod, SA
    [J]. CANCER CAUSES & CONTROL, 2005, 16 (06) : 667 - 674
  • [39] Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    Jernström, H
    Lubinski, J
    Lynch, HT
    Ghadirian, P
    Neuhausen, S
    Isaacs, C
    Weber, BL
    Horsman, D
    Rosen, B
    Foulkes, WD
    Friedman, E
    Gershoni-Baruch, R
    Ainsworth, P
    Daly, M
    Garber, J
    Olsson, H
    Sun, P
    Narod, SA
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (14) : 1094 - 1098
  • [40] Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers
    Lee, Y. C.
    Milne, R. L.
    Lheureux, S.
    Friedlander, M.
    McLachlan, S. A.
    Martin, K. L.
    Bernardini, M. Q.
    Smith, C.
    Picken, S.
    Nesci, S.
    Hopper, J. L.
    Phillips, K. A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 84 : 114 - 120